ArticleDigestive diseases and sciences2018
Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma.
Article in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 68 citations in OpenAlex.
- Advances in the mechanisms of extracellular vesicles and circulating tumor cells in hepatocellular carcinoma metastasis (Review).Molecular medicine reports · 2026Review
- Detection of Circulating Tumor Cells with an Epithelial-to-Mesenchymal Transition Phenotype.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Noncoding RNAs: A Novel Frontier in Liver Cancer Research and Therapy: Implications for Precision Oncology.Sub-cellular biochemistry · 2026Review
- Circulating tumor cells: mechanisms and clinical significance in colorectal cancer metastasis.Molecular cancer · 2025Review
- Ezrin Polarization as a Diagnostic Marker for Circulating Tumor Cells in Hepatocellular Carcinoma.Cells · 2024Article
- Anesthetic Approaches and Their Impact on Cancer Recurrence and Metastasis: A Comprehensive Review.Cancers · 2024Review
- The Role of Anesthetic Management in Lung Cancer Recurrence and Metastasis: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Emerging Prognostic Markers in Patients Undergoing Liver Resection for Hepatocellular Carcinoma: A Narrative Review.Cancers · 2024Review
- Clinical Application of Different Liquid Biopsy Components in Hepatocellular Carcinoma.Journal of personalized medicine · 2024Review
- Development and validation of nomogram to predict overall survival and disease-free survival after surgical resection in elderly patients with hepatocellular carcinoma.Frontiers in oncology · 2024Article
- Circulating Tumor Cells as a Promising Tool for Early Detection of Hepatocellular Carcinoma.Cells · 2023Review
- Liquid Biopsy in Hepatocellular Carcinoma: The Significance of Circulating Tumor Cells in Diagnosis, Prognosis, and Treatment Monitoring.International journal of molecular sciences · 2023Review
- Dynamics of Peripheral Blood Immune Cells during the Perioperative Period after Digestive System Resections: A Systematic Analysis of the Literature.Journal of clinical medicine · 2023Article
- Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma.BMC cancer · 2023Article
- Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights.Journal of hepatocellular carcinoma · 2023Review
- Association of circulating tumor cells andFrontiers in oncology · 2023Article
- Diabetic hyperglycemia promotes primary tumor progression through glycation-induced tumor extracellular matrix stiffening.Science advances · 2022Article
- Circulating tumor cells as a prognostic biomarker in patients with hepatocellular carcinoma.Scientific reports · 2022Article
- Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma.Journal of liver cancer · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating tumors cells (CTCs) may be a promising prognostic marker for patients with malignant tumors. However, there are few reports regarding its value for hepatocellular carcinoma (HCC) patients.
aimsTo investigate CTCs with epithelial and mesenchymal phenotypes as a potential prognostic biomarker for HCC patients.
methodsPeripheral blood samples were obtained from 165 HCC patients before radical surgery. CTCs were isolated via the CanPatrol CTC enrichment technique and classified using epithelial-mesenchymal transition (EMT) markers. The relationship of CTC phenotype with clinicopathological factors and HCC recurrence in patients was analyzed.
resultsCTC-positive status (count ≥ 2/5 mL) was found in 70.9% of the 165 HCC patients. Increased CTC number was more common in patients with higher AFP levels, multiple tumors, advanced TNM and BCLC staging, and presence of embolus or microembolus (P < 0.05). CTCs heterogeneity was noted using EMT markers. Mesenchymal CTCs were significantly correlated with high AFP levels, multiple tumors, advanced TNM and BCLC stage, presence of embolus or microembolus, and earlier recurrence (P < 0.05). The presence of mesenchymal CTCs predicted the shortest relapse-free survival, followed by mixed phenotypic CTCs, and then epithelial CTCs (P < 0.001).
conclusionCTC phenotype may serve as a prognostic indicator for HCC patients. CTCs assessment should include phenotypic identification tailored to characterize cells based on epithelial and mesenchymal markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.